TY - JOUR
T1 - Abnormalities of laboratory coagulation tests versus clinically evident coagulopathic bleeding
T2 - results from the prehospital resuscitation on helicopters study (PROHS)
AU - PROHS Study Group
AU - Chang, Ronald
AU - Fox, Erin E.
AU - Greene, Thomas J.
AU - Swartz, Michael D.
AU - DeSantis, Stacia M.
AU - Stein, Deborah M.
AU - Bulger, Eileen M.
AU - Melton, Sherry M.
AU - Goodman, Michael D.
AU - Schreiber, Martin A.
AU - Zielinski, Martin D.
AU - O'Keeffe, Terence
AU - Inaba, Kenji
AU - Tomasek, Jeffrey S.
AU - Podbielski, Jeanette M.
AU - Appana, Savitri
AU - Yi, Misung
AU - Johansson, Pär I.
AU - Henriksen, Hanne H.
AU - Stensballe, Jakob
AU - Steinmetz, Jacob
AU - Wade, Charles E.
AU - Holcomb, John B.
AU - Wade, Charles E.
AU - Podbielski, Jeanette M.
AU - Tomasek, Jeffrey S.
AU - del Junco, Deborah J.
AU - Swartz, Michael D.
AU - DeSantis, Stacia M.
AU - Appana, Savitri N.
AU - Greene, Thomas J.
AU - Yi, Misung
AU - Gonzalez, Michael O.
AU - Baraniuk, Sarah
AU - van Belle, Gerald
AU - Leroux, Brian G.
AU - Howard, Carrie L.
AU - Haymaker, Amanda
AU - Scalea, Thomas M.
AU - Ayd, Benjamin
AU - Das, Pratik
AU - Herrera, Anthony V.
AU - Robinson, Bryce R.H.
AU - Klotz, Patricia
AU - Minhas, Aniqa
AU - Kerby, Jeffrey D.
AU - Melton, Sherry M.
AU - Williams, Carolyn R.
AU - Stephens, Shannon W.
AU - Goodman, Michael
N1 - Funding Information:
The Prehospital Resuscitation on Helicopter Study (PROHS) was sponsored by the U.S. National Heart, Lung, and Blood Institute (U01HL077863) and the US Department of Defense. R.C. is supported by a T32 fellowship (grant no. 5T32GM008792) from the National Institute of General Medical Sciences (5T32GM008792). The opinions or conclusions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of any sponsor.
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background: Laboratory-based evidence of coagulopathy (LC) is observed in 25-35% of trauma patients, but clinically-evident coagulopathy (CC) is not well described. Methods: Prospective observational study of adult trauma patients transported by helicopter from the scene to nine Level 1 trauma centers in 2015. Patients meeting predefined highest-risk criteria were divided into CC+ (predefined as surgeon-confirmed bleeding from uninjured sites or injured sites not controllable by sutures) or CC-. We used a mixed-effects, Poisson regression with robust error variance to test the hypothesis that abnormalities on rapid thrombelastography (r-TEG) and international normalized ratio (INR) were independently associated with CC+. Results: Of 1,019 highest-risk patients, CC+ (n=41, 4%) were more severely injured (median ISS 32 vs 17), had evidence of LC on r-TEG and INR, received more transfused blood products at 4 hours (37 vs 0 units), and had greater 30-day mortality (59% vs 12%) than CC- (n=978, 96%). The overall incidence of LC was 39%. 30-day mortality was 22% vs 9% in those with and without LC. In two separate models, r-TEG K-time >2.5 min (RR 1.3, 95% CI 1.1-1.7), r-TEG mA <55 mm (RR 2.5, 95% CI 2.0-3.2), platelet count <150 x 109/L (RR 1.2, 95% CI 1.1-1.3), and INR >1.5 (RR 5.4, 95% CI 1.8-16.3) were independently associated with CC+. A combined regression model was not generated because too few patients underwent both r-TEG and INR. Conclusion: CC was rare compared to LC. CC was associated with poor outcomes and impairment of both clotting factor and platelet-mediated coagulation components.
AB - Background: Laboratory-based evidence of coagulopathy (LC) is observed in 25-35% of trauma patients, but clinically-evident coagulopathy (CC) is not well described. Methods: Prospective observational study of adult trauma patients transported by helicopter from the scene to nine Level 1 trauma centers in 2015. Patients meeting predefined highest-risk criteria were divided into CC+ (predefined as surgeon-confirmed bleeding from uninjured sites or injured sites not controllable by sutures) or CC-. We used a mixed-effects, Poisson regression with robust error variance to test the hypothesis that abnormalities on rapid thrombelastography (r-TEG) and international normalized ratio (INR) were independently associated with CC+. Results: Of 1,019 highest-risk patients, CC+ (n=41, 4%) were more severely injured (median ISS 32 vs 17), had evidence of LC on r-TEG and INR, received more transfused blood products at 4 hours (37 vs 0 units), and had greater 30-day mortality (59% vs 12%) than CC- (n=978, 96%). The overall incidence of LC was 39%. 30-day mortality was 22% vs 9% in those with and without LC. In two separate models, r-TEG K-time >2.5 min (RR 1.3, 95% CI 1.1-1.7), r-TEG mA <55 mm (RR 2.5, 95% CI 2.0-3.2), platelet count <150 x 109/L (RR 1.2, 95% CI 1.1-1.3), and INR >1.5 (RR 5.4, 95% CI 1.8-16.3) were independently associated with CC+. A combined regression model was not generated because too few patients underwent both r-TEG and INR. Conclusion: CC was rare compared to LC. CC was associated with poor outcomes and impairment of both clotting factor and platelet-mediated coagulation components.
UR - http://www.scopus.com/inward/record.url?scp=85039165623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039165623&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2017.10.050
DO - 10.1016/j.surg.2017.10.050
M3 - Article
C2 - 29289392
AN - SCOPUS:85039165623
SN - 0039-6060
VL - 163
SP - 819
EP - 826
JO - Surgery (United States)
JF - Surgery (United States)
IS - 4
ER -